光生物调节治疗头颈癌患者放疗所致味觉障碍：一项初步随机临床试验。
完整摘要 · 中文译文
味觉障碍是接受放疗的头颈癌（HNC）患者常见的并发症，可能对营养状况和生活质量产生负面影响。本预试验评估了光生物调节（PBM）对放疗所致味觉障碍管理的影响。16例接受头颈癌放疗的患者被随机分配至PBM组（n = 8）或硫酸锌组（n = 8）。在三个时间点进行客观味觉识别测试，评估甜、苦、酸、咸味：放疗前（T0）、第15次放疗时（T1）和第30次放疗时（T2）。咸味是两组中受影响最大的味觉模态。在T2时，锌组75.0%的患者和PBM组50.0%的患者能够正确识别甜味。相比之下，PBM组87.5%的患者和锌组75.0%的患者苦味得以保留。酸味在PBM组和锌组分别有87.5%和62.5%的患者得以保留，而咸味分别在两组中有50.0%和25.0%的患者得以保留。在T0、T1或T2时，组间均未观察到统计学显著差异（所有p > 0.05）。尽管未发现统计学显著差异，PBM与更好的酸味、苦味和咸味感知保留相关，尤其是在第30次放疗后。这些初步研究结果表明，PBM可能代表一种有前景的支持性策略，用于管理接受放疗的头颈癌患者的治疗相关味觉障碍。 放射治疗。
完整摘要 · 英文原文
Dysgeusia is a frequent complication in patients with head and neck cancer (HNC) undergoing radiotherapy and may negatively affect nutritional status and quality of life. This pilot study evaluated the effect of photobiomodulation (PBM) on the management of radiotherapy-induced dysgeusia. Sixteen patients undergoing radiotherapy for HNC were randomly assigned to either a PBM group (n = 8) or a zinc sulfate group (n = 8). Objective taste identification tests evaluating sweet, bitter, sour, and salty tastes were performed at three time points: before radiotherapy (T0), at the 15th radiotherapy session (T1), and at the 30th radiotherapy session (T2). Salty taste was the most affected taste modality in both groups. At T2, sweet taste was correctly identified by 75.0% of patients in the zinc group and 50.0% in the PBM group. In contrast, bitter taste was preserved in 87.5% of patients in the PBM group and 75.0% in the zinc group. Sour taste was preserved in 87.5% and 62.5% of patients in the PBM and zinc groups, respectively, whereas salty taste was preserved in 50.0% and 25.0% of patients, respectively. No statistically significant differences were observed between groups at T0, T1, or T2 (all p > 0.05). Although no statistically significant differences were identified, PBM was associated with better preservation of sour, bitter, and salty taste perception, particularly after the 30th radiotherapy session. These preliminary findings suggest that PBM may represent a promising supportive strategy for the management of treatment-related dysgeusia in patients with HNC undergoing radiotherapy.